Geode Capital Management LLC Lowers Position in Capricor Therapeutics Inc (NASDAQ:CAPR)

Geode Capital Management LLC decreased its holdings in shares of Capricor Therapeutics Inc (NASDAQ:CAPR) by 0.5% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 638,189 shares of the biotechnology company’s stock after selling 3,384 shares during the period. Geode Capital Management LLC owned approximately 1.41% of Capricor Therapeutics worth $9,708,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in CAPR. State Street Corp boosted its position in shares of Capricor Therapeutics by 27.8% during the 3rd quarter. State Street Corp now owns 512,313 shares of the biotechnology company’s stock valued at $7,792,000 after acquiring an additional 111,291 shares during the last quarter. Point72 Asset Management L.P. bought a new stake in Capricor Therapeutics during the third quarter valued at approximately $3,806,000. PFM Health Sciences LP purchased a new position in Capricor Therapeutics in the 3rd quarter worth approximately $2,324,000. Renaissance Technologies LLC increased its holdings in shares of Capricor Therapeutics by 158.7% in the 2nd quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company’s stock worth $656,000 after buying an additional 84,350 shares during the last quarter. Finally, Marshall Wace LLP purchased a new stake in shares of Capricor Therapeutics during the 2nd quarter valued at $426,000. 21.68% of the stock is currently owned by hedge funds and other institutional investors.

Capricor Therapeutics Price Performance

CAPR opened at $13.80 on Thursday. Capricor Therapeutics Inc has a 1 year low of $3.52 and a 1 year high of $23.40. The stock’s 50 day simple moving average is $16.95 and its 200 day simple moving average is $10.78. The firm has a market cap of $627.49 million, a price-to-earnings ratio of -13.02 and a beta of 3.98.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and issued a $77.00 target price on shares of Capricor Therapeutics in a research report on Thursday, November 14th. Cantor Fitzgerald increased their price objective on Capricor Therapeutics from $25.00 to $30.00 and gave the company an “overweight” rating in a research report on Thursday, November 14th. Maxim Group boosted their target price on Capricor Therapeutics from $12.00 to $25.00 and gave the stock a “buy” rating in a research report on Wednesday, September 25th. Oppenheimer reiterated an “outperform” rating and set a $15.00 price target on shares of Capricor Therapeutics in a research report on Monday, September 23rd. Finally, Piper Sandler began coverage on shares of Capricor Therapeutics in a research note on Monday, October 21st. They set an “overweight” rating and a $35.00 price target on the stock. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $34.50.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.